| Name | Title | Contact Details |
|---|
Western Health is a Stephenville Crossing, NL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
First Choice Health is a Seattle-based, physician and hospital owned company that has served Washington and the Northwest since 1985. We now serve well over one million people with our array of products and services. First Choice Health`s Preferred Provider Organization (PPO) is recognized as the leading independent PPO Network in Washington and Oregon, with a growing regional presence in Alaska, Idaho, Montana, Wyoming, and beyond. Combined our network offers over 120,000 directly contracted and credentialed providers and 369 hospitals used by a wide variety of insurance companies, third party administrators, and plan sponsors. In addition to our PPO Network, First Choice Health offers Medical Management Services, an Employee Assistance Program (EAP), a Physician Assistance Program (PAP), and Health Plan Administration (HPA).
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
t+ Clinical is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mission Search USA is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.